Skip to content

阿尔托神经科学

US · ANRO #3301 按市值排名 上市于 2024
21.94 -0.68 -3.01%
实时 - 追踪5344个代码 - 心跳于370秒前 · 2026-10-16 19:30

最新新闻

  • 评级变动
    Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)
    TipRanks · 2026/6/26
  • 评级变动
    BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $37
    \u5e02\u573a\u8d44\u8baf · 2026/8/13
  • 评级变动
    Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Guardian Pharmacy Services, Inc. Class A (GRDN) and Alto Neuroscience, Inc. (ANRO)
    TipRanks · 2026/6/17
  • 评级变动
    Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)
    TipRanks · 2026/7/14
  • 评级变动
    H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO)
    TipRanks · 2026/6/25
  • 评级变动
    H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $55
    \u5e02\u573a\u8d44\u8baf · 2026/8/17
  • 评级变动
    Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)
    TipRanks · 2026/8/14
  • Alto Neuroscience(ANRO.US) Officer Sells US$3.57 Million in Common Stock
    \u5e02\u573a\u8d44\u8baf · 2026/10/2
  • 评级变动
    BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $37
    \u5e02\u573a\u8d44\u8baf · 2026/8/13
  • 评级变动
    BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $28
    \u5e02\u573a\u8d44\u8baf · 2026/7/14
  • Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Phreesia (PHR)
    TipRanks · 2026/10/3
  • Alto Neuroscience, Inc. (ANRO) Receives a Buy From Jefferies
    TipRanks · 2026/8/13
  • 评级变动
    BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/8/14
  • 评级变动
    Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $40
    \u5e02\u573a\u8d44\u8baf · 2026/8/13
  • 评级变动
    H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $50
    \u5e02\u573a\u8d44\u8baf · 2026/6/25
  • H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $55
    \u5e02\u573a\u8d44\u8baf · 2026/9/22
  • 评级变动
    Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT)
    TipRanks · 2026/8/13
  • 评级变动
    Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and BridgeBio Pharma (BBIO)
    TipRanks · 2026/6/16
  • William Blair Maintains Alto Neuroscience(ANRO.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/10/3
  • 评级变动
    JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $44
    \u5e02\u573a\u8d44\u8baf · 2026/6/26

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

阿尔托神经科学 讨论区 0 条评论

发表评论